 Leap Therapeutics, Inc. Nasdaq: LPTX, a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. Nasdaq: BGNE; HKEX: 06160, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leaps anti-Dickkopf-1 DKK1 antibody, in Asia excluding Japan, Australia, and New Zealand. Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for a 27 million equity financing with BeiGene and two institutional investors. 